{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:43:30Z","timestamp":1761561810031},"reference-count":37,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1111\/jcpt.12107","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T09:12:35Z","timestamp":1383642755000},"page":"102-105","source":"Crossref","is-referenced-by-count":10,"title":["Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report"],"prefix":"10.1155","volume":"39","author":[{"given":"G.","family":"Kaiafa","sequence":"first","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kakaletsis","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Savopoulos","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Perifanis","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giannouli","sequence":"additional","affiliation":[{"name":"Department of Pathology; Theagenio Cancer Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery; Euromedica - Blue Cross Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zisekas","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.I.","family":"Hatzitolios","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine; Medical School; Aristotle University of Thessaloniki; AHEPA University Hospital; Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"10.1111\/jcpt.12107-BIB0001|jcpt12107-cit-0001","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12107-BIB0002|jcpt12107-cit-0002","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12107-BIB0003|jcpt12107-cit-0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12107-BIB0004|jcpt12107-cit-0004","unstructured":"European Medicines Agency. Sprycel (dasatinib): summary of product characteristics http:\/\/www.ema.europa.eu"},{"key":"10.1111\/jcpt.12107-BIB0005|jcpt12107-cit-0005","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12107-BIB0006|jcpt12107-cit-0006","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jcpt.12107-BIB0007|jcpt12107-cit-0007","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/jcpt.12107-BIB0008|jcpt12107-cit-0008","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jcpt.12107-BIB0009|jcpt12107-cit-0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","author":"Wong","year":"2009","journal-title":"J Hematol Oncol."},{"key":"10.1111\/jcpt.12107-BIB0010|jcpt12107-cit-0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2710.2008.00916.x","article-title":"Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance to imatinib and renal failure","volume":"33","author":"Sonmez","year":"2008","journal-title":"J Clin Pharm Therap"},{"key":"10.1111\/jcpt.12107-BIB0011|jcpt12107-cit-0011","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1111\/jcpt.12107-BIB0012|jcpt12107-cit-0012","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"10.1111\/jcpt.12107-BIB0013|jcpt12107-cit-0013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","article-title":"Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors","volume":"4","author":"Kelly","year":"2009","journal-title":"Target Oncol"},{"key":"10.1111\/jcpt.12107-BIB0014|jcpt12107-cit-0014","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"10.1111\/jcpt.12107-BIB0015|jcpt12107-cit-0015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12107-BIB0016|jcpt12107-cit-0016","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MAJ.0b013e3181ae9227","article-title":"Dasatinib-induced pleural effusions: a lymphatic network disorder?","volume":"338","author":"Goldblatt","year":"2009","journal-title":"Am J Med Sc"},{"key":"10.1111\/jcpt.12107-BIB0017|jcpt12107-cit-0017","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO.2002.99.179","article-title":"Hypersensitivity pneumonitis related to imatinib mesylate","volume":"20","author":"Bergeron","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12107-BIB0018|jcpt12107-cit-0018","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12107-BIB0019|jcpt12107-cit-0019","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12107-BIB0020|jcpt12107-cit-0020","first-page":"363","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1111\/jcpt.12107-BIB0021|jcpt12107-cit-0021","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quinta\u2032s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12107-BIB0022|jcpt12107-cit-0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-011-0921-9","article-title":"Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy","volume":"94","author":"Kim","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1111\/jcpt.12107-BIB0023|jcpt12107-cit-0023","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12107-BIB0024|jcpt12107-cit-0024","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/jcpt.12107-BIB0025|jcpt12107-cit-0025","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1345\/aph.1G131","article-title":"Acute renal failure secondary to imatinib mesylate treatment in prostate cancer","volume":"39","author":"Foringer","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12107-BIB0026|jcpt12107-cit-0026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","article-title":"Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss","volume":"51","author":"Fran\u00e7ois","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12107-BIB0027|jcpt12107-cit-0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","article-title":"Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature","volume":"34","author":"Gafter-Gvili","year":"2010","journal-title":"Leukemia Res"},{"key":"10.1111\/jcpt.12107-BIB0028|jcpt12107-cit-0028","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/annonc\/mdf304","article-title":"Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase","volume":"13","author":"Vora","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12107-BIB0029|jcpt12107-cit-0029","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2002.20.1.354","article-title":"Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"20","author":"Dann","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12107-BIB0030|jcpt12107-cit-0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.leukres.2006.05.005","article-title":"Tumour lysis syndrome with acute renal failure during imatinib therapy","volume":"31","author":"Ali","year":"2007","journal-title":"Leuk Res"},{"key":"10.1111\/jcpt.12107-BIB0031|jcpt12107-cit-0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08860220903391226","article-title":"Acute Renal Failure under Dasatinib Therapy","volume":"32","author":"Ozkurt","year":"2010","journal-title":"Ren Fail"},{"key":"10.1111\/jcpt.12107-BIB0032|jcpt12107-cit-0032","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.leukres.2008.07.029","article-title":"Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia","volume":"33","author":"Holstein","year":"2009","journal-title":"Leuk Res"},{"key":"10.1111\/jcpt.12107-BIB0033|jcpt12107-cit-0033","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"Christopher","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12107-BIB0034|jcpt12107-cit-0034","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1681\/ASN.2004050392","article-title":"Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice","volume":"16","author":"Lassila","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12107-BIB0035|jcpt12107-cit-0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2733fje","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"Faseb J"},{"key":"10.1111\/jcpt.12107-BIB0036|jcpt12107-cit-0036","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1002\/art.21424","article-title":"Amelioration of autoimmune nephritis by imatinib in MRL\/lpr mice","volume":"52","author":"Sadanaga","year":"2005","journal-title":"Arthrit Rheum"},{"key":"10.1111\/jcpt.12107-BIB0037|jcpt12107-cit-0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ki.5001528","article-title":"Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease","volume":"70","author":"Zoja","year":"2006","journal-title":"Kidney Int"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12107\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:06Z","timestamp":1671818706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12107","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,5]]}}}